Results 1 to 10 of about 745,289 (215)

Targeting Ultrasmall Gold Nanoparticles with cRGD Peptide Increases the Uptake and Efficacy of Cytotoxic Payload [PDF]

Nanomaterials, 2022
Cyclic arginyl-glycyl-aspartic acid peptide (cRGD) peptides show a high affinity towards αVβ3 integrin, a receptor overexpressed in many cancers. We aimed to combine the versatility of ultrasmall gold nanoparticles (usGNP) with the target selectivity of ...
Richard D. Perrins, Lee-Anne McCarthy, Angela Robinson, Kelly L. Spry, Valentin Cognet, Avelino Ferreira, John Porter, Cristina Espinosa Garcίa, Miguel Ángel Rodriguez, Diana Lopez, Ibon Perera, Kelly Conlon, Africa Barrientos, Tom Coulter, Alessandro Pace, Sarah J. M. Hale, Enrico Ferrari, Csanad Z. Bachrati   +17 more
doaj   +7 more sources

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells [PDF]

Frontiers in Pharmacology, 2019
Antibody-drug conjugates (ADCs) are composed of an antibody linked to cytotoxic anticancer payloads. ADCs recognize tumor-specific cell surface antigens and are internalized into lysosomes where proteolytic enzymes release the cytotoxic payloads.
Peggy Liu-Kreyche, Hong Shen, Anthony M. Marino, Ramaswamy A. Iyer, W. Griffith Humphreys, Yurong Lai   +5 more
doaj   +6 more sources

Facile protein conjugation of platinum for light-activated cytotoxic payload release.

Chem Commun (Camb), 2021
The novel Pt(iv) complex trans,trans-[Pt(N3)2(Py)2(OH)(OCO-(PEG)2-NHCSNH-Ph-NCS)] (Pt4) conjugates to the side chain of lysine amino acids in proteins under mild conditions.
Imberti C, Lermyte F, Friar EP, O'Connor PB, Sadler PJ.   +4 more
europepmc   +5 more sources

Adnectin-drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors. [PDF]

Protein Eng Des Sel, 2018
Tumor-specific delivery of cytotoxic agents remains a challenge in cancer therapy. Antibody–drug conjugates (ADC) deliver their payloads to tumor cells that overexpress specific tumor-associated antigens—but the multi-day half-life of ADC leads to high ...
Lipovšek D, Carvajal I, Allentoff AJ, Barros A, Brailsford J, Cong Q, Cotter P, Gangwar S, Hollander C, Lafont V, Lau WL, Li W, Moreta M, O'Neil S, Pinckney J, Smith MJ, Su J, Terragni C, Wallace MA, Wang L, Wright M, Marsh HN, Bryson JW.   +22 more
europepmc   +5 more sources

Monomethyl Auristatin E, a Potent Cytotoxic Payload for Development of Antibody-Drug Conjugates against Breast Cancer

Novelty in Biomedicine, 2017
Background: Breast cancer is a heterogeneous disease characterized by differential responses to targeted and chemotherapeutic agents. Antibody-drug conjugates are one of the promising strategies for the treatment of breast cancer. Monomethyl auristatin E
Meghdad Abdollahpour-alitappeh, Amir Amanzadeh, Fatemeh Heidarnejad, Mahdi Habibi-Anbouhi, Majid Lotfinia, Sepand Razavi-vakhshourpour, Saeed Jahandideh, Hamid Najminejad, Saeed Balalaie, Mohsen Abolhassani   +9 more
doaj   +3 more sources

Payload diversification: a key step in the development of antibody–drug conjugates

Journal of Hematology & Oncology, 2023
Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that currently combines the selectivity of monoclonal antibodies with the potency of a payload consisting of cytotoxic agents. For many years microtubule targeting and DNA-
Louise Conilh, Lenka Sadilkova, Warren Viricel, Charles Dumontet   +3 more
doaj   +2 more sources

A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization [PDF]

Clinical Cancer Research, 2019
Purpose: HER3 is a compelling target for cancer treatment; however, no HER3-targeted therapy is currently clinically available. Here, we produced U3-1402, an anti-HER3 antibody–drug conjugate with a topoisomerase I inhibitor exatecan derivative (DXd ...
Y. Hashimoto, K. Koyama, Y. Kamai, Kenji Hirotani, Y. Ogitani, Akiko Zembutsu, Manabu Abe, Y. Kaneda, N. Maeda, Y. Shiose, Takuma Iguchi, Tomomichi Ishizaka, Tsuyoshi Karibe, I. Hayakawa, K. Morita, T. Nakada, T. Nomura, K. Wakita, T. Kagari, Yuki Abe, M. Murakami, Suguru Ueno, T. Agatsuma   +22 more
semanticscholar   +3 more sources

A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer

Pharmaceutics, 2023
Antibody-drug conjugates (ADCs) have demonstrated a great therapeutic potential against cancer due to their target specificity and cytotoxicity. To exert a maximum therapeutic effect on cancerous cells, we have conjugated two different payloads to ...
Candice Maria Mckertish, Veysel Kayser
doaj   +2 more sources

Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?

Current Cancer Therapy Reviews, 2016
Over the last decade, Antibody Drug Conjugates (ADCs) have gained a great success due to their documented clinical efficacy and manageable toxicity. Generally the word "drug" is associated with a che-motherapeutic drug, however "drug" can also be associated with other cy-totoxic payloads such as radionuclides, termed more specifically, Anti-body ...
J. Chatal, F. Kraeber-Bodéré, C. Bodet-Milin, C. Rousseau   +3 more
semanticscholar   +4 more sources

Frontiers in Antibody–Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy [PDF]

Pharmaceuticals
Antibody–drug conjugates (ADCs) represent a transformative class of targeted therapies designed to deliver potent cytotoxic agents specifically to tumor cells, minimizing systemic toxicity. This review provides a comprehensive overview of ADCs, detailing
Xinghan Li, Jiaming Liu, Yitong Meng, Jun Li, Jieling Zhao, Dequan Liu, Xiaodong Zhang   +6 more
doaj   +2 more sources